Oreofe Odejide is an Oncology physician affiliated with Harvard University. OpenAlex indexes 144 publications with 2,876 citations (h-index 25); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- HEME Home Transfusion Program
Sponsor: Dana-Farber Cancer Institute
- Home Transfusion for HEME
Sponsor: Dana-Farber Cancer Institute
- UPLYFT For Lymphoma Survivors
Sponsor: Dana-Farber Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
40%Short-acting sulfonamides40%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsCancer & immunology
32.5%Kinase inhibitor32.5%Calquence100%Part D<11 patientsDermatology
27.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor27.5%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2017–2024 per NIH RePORTER. The latest:
- HEME-Hospice: An Intervention to improve Hospice Use for Patients with Hematologic Malignancies
Dana-Farber Cancer Inst
FY2024$731,526R37CA289639 - Improving Hospice Use for Patients with Blood Cancers
Dana-Farber Cancer Inst
FY2022$127,276K08CA218295 - Improving Hospice Use for Patients with Blood Cancers
Dana-Farber Cancer Inst
FY2021$169,702K08CA218295
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy
Journal of Allergy and Clinical Immunology
2024 - Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study
BMJ Supportive & Palliative Care
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Thoralf Sundt, MD
Harvard University
Felipe Fregni, MD, MPH
Harvard University
Joseph Antin, MD
Harvard University
Sarah Fortune, MD
Harvard University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”